Open AccessAbstract 1923: KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz)
Author(s) -
Rekha Pal,
Ashok Srinivasan,
Peter C. Lucas,
Carmen J. Allegra,
Angela M. Davies,
Alshad S. Lalani,
Samuel A. Jacobs,
Katherine L. Pogue–Geile
Publication year - 2019
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1158/1538-7445.sabcs18-1923
Subject(s) - trametinib , organoid , kras , neratinib , colorectal cancer , medicine , cancer research , trastuzumab , cancer , oncology , biology , breast cancer , mapk/erk pathway , kinase , microbiology and biotechnology , genetics